...
首页> 外文期刊>Palliative medicine >Symptom management for the adult patient dying with advanced chronic kidney disease: a review of the literature and development of evidence-based guidelines by a United Kingdom Expert Consensus Group.
【24h】

Symptom management for the adult patient dying with advanced chronic kidney disease: a review of the literature and development of evidence-based guidelines by a United Kingdom Expert Consensus Group.

机译:死于晚期慢性肾脏病的成年患者的症状管理:英国专家共识小组对文献的回顾和循证指南的发展。

获取原文
获取原文并翻译 | 示例
   

获取外文期刊封面封底 >>

       

摘要

Improvement in end-of-life-care is required for patients dying with chronic kidney disease (CKD). The UK government now recommends that tools such as the Liverpool Care Pathway for the Dying Patient (LCP) be used to enhance the care of those patients dying with CKD. The LCP was originally developed for patients dying with terminal cancer, however has been shown to be transferable to patients dying with heart failure or stroke. On this background, in 2005 a UK National Renal LCP Steering Group was formed. The aim was to determine whether or not the generic LCP was transferable to patients dying with CKD. An Expert Consensus sub-group was established to produce evidence-based prescribing guidelines to allow safe and effective symptom control for patients dying with renal failure. These guidelines were finalised by the Expert Consensus group in August 2007 and endorsed by the Department of Health in March 2008. A literature search on symptom control and end-of-life care in renal failure was performed. A summary of the evidence was presented at a National Steering Group meeting. Opinions were given and provisional guidelines discussed. A first draft was produced and individually reviewed by all members of the Expert Group. Following review, amendments were made and a second draft written. This was presented to the entire National Steering Group and again individual comments were taken into consideration. A third and fourth draft were written and individually reviewed, before the guidelines were finalised by the Expert Consensus group. Patients dying with advanced CKD suffer symptoms similar to patients dying of cancer. The Renal LCP prescribing guidelines aim to control the same symptoms as the generic LCP: pain, dyspnoea, terminal restlessness and agitation, nausea and respiratory tract secretions. The evidence for the production of the guidelines is discussed and how a consensus was reached. A summary of the guidelines is given and the complete guidelines document is available via the Marie Curie Palliative Care Institute, Liverpool website.
机译:垂死于慢性肾脏疾病(CKD)的患者需要改善临终护理。英国政府现在建议使用诸如“临终患者的利物浦护理途径”(LCP)之类的工具来增强对那些死于CKD的患者的护理。 LCP最初是为死于晚期癌症的患者而开发的,但已证明可将其转移到死于心力衰竭或中风的患者中。在此背景下,2005年成立了英国国家肾脏LCP指导小组。目的是确定通用LCP是否可转移至死于CKD的患者。建立了专家共识小组,以制定基于证据的处方指南,从而为死于肾衰竭的患者提供安全有效的症状控制。这些指南由专家共识小组于2007年8月最终确定,并于2008年3月获得卫生部的认可。对肾衰竭的症状控制和生命终止治疗进行了文献检索。在国家指导小组会议上提出了证据的摘要。提出了意见并讨论了临时准则。编写了初稿,并由专家组的所有成员进行了单独审查。审查之后,进行了修订,并编写了第二稿。这已提交给整个国家指导小组,并再次考虑了个人意见。在专家共识小组最终确定指南之前,编写了第三稿和第四稿并进行了单独审核。死于晚期CKD的患者遭受的症状类似于死于癌症的患者。肾脏LCP处方指南旨在控制与一般LCP相同的症状:疼痛,呼吸困难,终末躁动不安和躁动,恶心和呼吸道分泌物。讨论了制定指南的证据以及如何达成共识。给出了指南的摘要,完整的指南文件可通过利物浦的玛丽居里姑息治疗研究所获得。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号